These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37630477)

  • 1. Safety and Tolerability of Six Months of Isoniazid Plus Pyridoxine or Three Months of Rifampicin for Tuberculosis among Subjects with Diabetes Mellitus: A Randomized Trial.
    Tamez-Torres KM; Mongua-Rodríguez N; Ferreyra-Reyes L; Torres-Gonzalez P; Delgado-Sánchez G; Martínez-Hernández M; Bobadilla-Del-Valle M; Jasso-Sosa VY; López-Castillo PDS; Ferreira-Guerrero E; Cruz-Hervert LP; Sifuentes-Osornio J; Aguilar-Salinas CA; García-García L; Ponce-de-Leon A
    Microorganisms; 2023 Jul; 11(8):. PubMed ID: 37630477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR; Trajman A; Cook VJ; Johnston JC; Adjobimey M; Ruslami R; Eisenbeis L; Fregonese F; Valiquette C; Benedetti A; Menzies D
    Lancet Infect Dis; 2020 Mar; 20(3):318-329. PubMed ID: 31866327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL; Goldberg HF
    Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial.
    Ntinginya NE; Te Brake L; Sabi I; Chamba N; Kilonzo K; Laizer S; Andia-Biraro I; Kibirige D; Kyazze AP; Ninsiima S; Critchley JA; Romeo R; van de Maat J; Olomi W; Mrema L; Magombola D; Mwayula IH; Sharples K; Hill PC; van Crevel R;
    Trials; 2022 Jun; 23(1):480. PubMed ID: 35689272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing antimycobacterial activity of isoniazid and rifampicin incorporated norbornene nanoparticles.
    Kumarasingam K; Vincent M; Mane SR; Shunmugam R; Sivakumar S; Uma Devi KR
    Int J Mycobacteriol; 2018; 7(1):84-88. PubMed ID: 29516891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of discrepant results between genotypic MTBDR
    Kang JY; Hur J; Kim S; Jeon S; Lee J; Kim YJ; Kim SC; Park YJ; Kim YK; Moon HS
    J Thorac Dis; 2019 Feb; 11(2):400-409. PubMed ID: 30962983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.
    LaCourse SM; Richardson BA; Kinuthia J; Warr AJ; Maleche-Obimbo E; Matemo D; Cranmer LM; Mecha J; Escudero JN; Hawn TR; John-Stewart G
    Clin Infect Dis; 2021 Jul; 73(2):e337-e344. PubMed ID: 32564076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis?
    Denkinger CM; Pai M; Dowdy DW
    PLoS One; 2014; 9(1):e84197. PubMed ID: 24404155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
    Fresard I; Bridevaux PO; Rochat T; Janssens JP
    Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial.
    Ruan QL; Huang XT; Yang QL; Liu XF; Wu J; Pan KC; Shen YJ; Cai LM; Ling Q; Jiang T; Hong JJ; Wang XD; Ma CL; Peng GQ; Wang XZ; Mao JC; Wu TZ; Lin MY; Shao LY; Zhang WH
    Clin Microbiol Infect; 2021 Apr; 27(4):576-582. PubMed ID: 32553881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
    Fregonese F; Ahuja SD; Akkerman OW; Arakaki-Sanchez D; Ayakaka I; Baghaei P; Bang D; Bastos M; Benedetti A; Bonnet M; Cattamanchi A; Cegielski P; Chien JY; Cox H; Dedicoat M; Erkens C; Escalante P; Falzon D; Garcia-Prats AJ; Gegia M; Gillespie SH; Glynn JR; Goldberg S; Griffith D; Jacobson KR; Johnston JC; Jones-López EC; Khan A; Koh WJ; Kritski A; Lan ZY; Lee JH; Li PZ; Maciel EL; Galliez RM; Merle CSC; Munang M; Narendran G; Nguyen VN; Nunn A; Ohkado A; Park JS; Phillips PPJ; Ponnuraja C; Reves R; Romanowski K; Seung K; Schaaf HS; Skrahina A; Soolingen DV; Tabarsi P; Trajman A; Trieu L; Banurekha VV; Viiklepp P; Wang JY; Yoshiyama T; Menzies D
    Lancet Respir Med; 2018 Apr; 6(4):265-275. PubMed ID: 29595509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against
    Hakkimane SS; Shenoy VP; Gaonkar SL; Bairy I; Guru BR
    Int J Nanomedicine; 2018; 13():4303-4318. PubMed ID: 30087562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.
    Kendall EA; Hussain H; Kunkel A; Kubiak RW; Trajman A; Menzies R; Drain PK
    BMC Med; 2021 Dec; 19(1):315. PubMed ID: 34903214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.